The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

LYPRESSIN     1-[[19-amino-10-(2- aminocarbonylethyl)-7...

Synonyms: Lipresina, Postacton, Diapid, Lipressina, Lypressine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of LYPRESSIN


Psychiatry related information on LYPRESSIN


High impact information on LYPRESSIN

  • The major pressor hormone of two Australian species, the red kangaroo (Macropus rufus) and the tammar (Macropus eugenii), has been identified as lysine vasopressin by its amino acid sequence anda its pharmacological properties [11].
  • A theoretical methodology for use in conjunction with experiment was applied to the neurohypophyseal hormone lysine vasopressin for elucidation of its accessible molecular conformations and associated flexibility, conformational transitions, and dynamics [12].
  • Male mice were given a single injection of either adrenocorticotropic hormone (ACTH) or lysine vasopressin immediately after a defeat in an encounter with an aggressive male mouse [13].
  • Human corticotropin-releasing factor plus lysine vasopressin test during glucocorticoid therapy [14].
  • Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP [15].

Chemical compound and disease context of LYPRESSIN


Biological context of LYPRESSIN


Anatomical context of LYPRESSIN


Associations of LYPRESSIN with other chemical compounds


Gene context of LYPRESSIN


Analytical, diagnostic and therapeutic context of LYPRESSIN


  1. Studies of the mechanism of contralateral polyuria after renal artery stenosis. Galvez, O.G., Roberts, B.W., Mishkind, M.H., Bay, W.H., Ferris, T.F. J. Clin. Invest. (1977) [Pubmed]
  2. In vivo and in vitro studies of urinary concentrating ability in potassium-depleted rabbits. Raymond, K.H., Davidson, K.K., McKinney, T.D. J. Clin. Invest. (1985) [Pubmed]
  3. Local gangrene: a complication of peripheral Pitressin therapy for bleeding esophageal varices. Greenwald, R.A., Rheingold, O.J., Chiprut, R.O., Rogers, A.I. Gastroenterology (1978) [Pubmed]
  4. Effect of donor age and sex on the outcome of liver transplantation. Marino, I.R., Doyle, H.R., Aldrighetti, L., Doria, C., McMichael, J., Gayowski, T., Fung, J.J., Tzakis, A.G., Starzl, T.E. Hepatology (1995) [Pubmed]
  5. Survival following infusion of Pitressin into the superior mesenteric artery to control bleeding esophageal varices in cirrhotic patients. Getzen, L.C., Brink, R.R., Wolfman, E.F. Ann. Surg. (1978) [Pubmed]
  6. Vasopressin-8-lysine in prevention of ECT-induced amnesia. Partap, M., Jos, C.J., Dye, C.J. The American journal of psychiatry. (1983) [Pubmed]
  7. The mechanism of urinary concentration in nephrogenic diabetes insipidus. McConnell, R.F., Lorentz, W.B., Berger, M., Smith, E.H., Carvajal, H.F., Travis, L.B. Pediatr. Res. (1977) [Pubmed]
  8. Human memory and neurohypophyseal hormones: opposite effects of vasopressin and oxytocin. Fehm-Wolfsdorf, G., Born, J., Voigt, K.H., Fehm, H.L. Psychoneuroendocrinology (1984) [Pubmed]
  9. Lack of effect of Pitressin on the learning ability of Brattleboro rats with diabetes insipidus using positively reinforced operant conditioning. Laycock, J.F., Gartside, I.B. Physiol. Behav. (1985) [Pubmed]
  10. Influence of neurohypophyseal peptides on the formation of active avoidance conditioned reflex behavior. Ibragimov, R.S.h. Neurosci. Behav. Physiol. (1990) [Pubmed]
  11. Phenypressin (Phe2-Arg8-vasopressin), a new neurohypophysial peptide found in marsupials. Chauvet, M.T., Hurpet, D., Chauvet, J., Acher, R. Nature (1980) [Pubmed]
  12. Dynamics and conformational energetics of a peptide hormone: vasopressin. Hagler, A.T., Osguthorpe, D.J., Dauber-Osguthorpe, P., Hempel, J.C. Science (1985) [Pubmed]
  13. ACTH and vasopressin treatments immediately after a defeat increase future submissiveness in male mice. Roche, K.E., Leshner, A.I. Science (1979) [Pubmed]
  14. Human corticotropin-releasing factor plus lysine vasopressin test during glucocorticoid therapy. Hashimoto, K., Suemaru, S., Takao, T., Sugawara, M., Hattori, T., Kageyama, J., Takahashi, K., Ota, Z. J. Clin. Invest. (1988) [Pubmed]
  15. Identification and characterization of a vasopressin isoreceptor in porcine seminal vesicles. Maggi, M., Kassis, S., Malozowski, S., Guardabasso, V., Rodbard, D. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  16. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. Arnaldi, G., Gasc, J.M., de Keyzer, Y., Raffin-Sanson, M.L., Perraudin, V., Kuhn, J.M., Raux-Demay, M.C., Luton, J.P., Clauser, E., Bertagna, X. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  17. Potentiation of the response to vasopressin (pitressin) by treatment with a combination of chlorpropamide and chlorothiazide in Brattleboro rats with hereditary hypothalamic diabetes insipidus. Laycock, J.F., Lewis, A.F. Br. J. Pharmacol. (1977) [Pubmed]
  18. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Boccara, G., Ouattara, A., Godet, G., Dufresne, E., Bertrand, M., Riou, B., Coriat, P. Anesthesiology (2003) [Pubmed]
  19. The effects of cortisol, 11-epicortisol, and lysine vasopressin on DNA and RNA synthesis in isolated human adrenocorticotropic hormone-secreting pituitary tumor cells. Resetić, J., Reiner, Z., Lüdecke, D., Riznar-Resetić, V., Sekso, M. Steroids (1990) [Pubmed]
  20. Overnight dexamethasone pre-treatment improves the performance of the lysine-vasopressin test in the diagnosis of Cushing's syndrome. Contreras, P., Araya, V. Clin. Endocrinol. (Oxf) (1996) [Pubmed]
  21. Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis. Douglas, J.G., Forrest, J.A., Prowse, C.V., Cash, J.D., Finlayson, N.D. Gut (1979) [Pubmed]
  22. Neurohypophysial peptides and central cardiovascular control. Montastruc, J.L., Dang Tran, L., Montastruc, P. Eur. Heart J. (1983) [Pubmed]
  23. The combined corticotropin-releasing hormone/lysine vasopressin test discloses a corticotroph phenotype. Bertagna, X., Coste, J., Raux-Demay, M.C., Letrait, M., Strauch, G. J. Clin. Endocrinol. Metab. (1994) [Pubmed]
  24. [3H]vasopressin binding to rat hippocampal synaptic plasma membrane. Kinetic and pharmacological characterization. Barberis, C. FEBS Lett. (1983) [Pubmed]
  25. Concomitant secretion of adrenocorticotropin, beta-endorphin, and gamma-melanotropin from perfused pituitary tumor cells of Cushing's disease: effects of lysine vasopressin, rat median eminence extracts, thyrotropin-releasing hormone, and luteinizing hormone-releasing hormone. Oki, S., Nakao, K., Tanaka, I., Horii, K., Nakai, Y., Shimbo, S., Watanabe, M., Nakane, T., Kuwayama, A., Kageyama, N., Imura, H. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  26. Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects. Imai, Y., Abe, K., Seino, M., Haruyama, T., Tajima, J., Sato, M., Goto, T., Hiwatari, M., Kasai, Y., Yoshinaga, K., Sekino, H. Hypertension (1982) [Pubmed]
  27. The effect of vasopressin on extracellular cation concentrations and muscle resting potentials in the rat. Gartside, I.B., Jones, A.M., Laycock, J.F., Walter, S.J. J. Physiol. (Lond.) (1981) [Pubmed]
  28. Divergent effects of long acting cyclic nucleotides and lysine vasopressin on the release of matrix sulfated proteoglycans into the medium of fetal rat chondrocytes in monolayer culture. Miller, R.P., Erickson-Lucas, M. J. Cell. Physiol. (1980) [Pubmed]
  29. Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. Perraudin, V., Delarue, C., De Keyzer, Y., Bertagna, X., Kuhn, J.M., Contesse, V., Clauser, E., Vaudry, H. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  30. A met-enkephalin analog inhibits adrenocorticotropin secretion by cultured pituitary cells from a patient with Nelson's syndrome. Lamberts, S.W., Oosterom, R., Verleun, T., Bons, E.G., Uitterlinden, P. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  31. Vasopressin receptor-mediated endocytosis in cells transfected with V1-type vasopressin receptors. Lutz, W., Sanders, M., Salisbury, J., Lolait, S., O'Carroll, A.M., Kumar, R. Kidney Int. (1993) [Pubmed]
  32. Oestrogen effects on urine concentrating response in young women. Stachenfeld, N.S., Taylor, H.S., Leone, C.A., Keefe, D.L. J. Physiol. (Lond.) (2003) [Pubmed]
  33. Studies on the corticotrophin-releasing activity of vasopressin, using ACTH secretion by cultured rat adenohypophyseal cells. Yasuda, N., Greer, M.A. Endocrinology (1976) [Pubmed]
  34. Responsiveness of hypophyseal-adrenocortical axis to repetitive administration of synthetic ovine corticotropin-releasing hormone in patients with isolated adrenocorticotropin deficiency. Koide, Y., Kimura, S., Inoue, S., Ikeda, M., Uchida, K., Ando, J., Shimizu, A., Oda, K., Itakura, M., Nabeshima, I. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  35. Blockade of alpha 2-adrenoceptors stimulates basal and stress-induced adrenocorticotropin secretion in the developing rat through a central mechanism independent from corticotropin-releasing factor and arginine vasopressin. Grino, M., Paulmyer-Lacroix, O., Faudon, M., Renard, M., Anglade, G. Endocrinology (1994) [Pubmed]
  36. Effects of repetitive administration of recombinant human interleukin-1 beta, an analog or corticotropin-releasing hormone combined with lysine vasopressin on rats with glucocorticoid-induced secondary adrenocortical insufficiency. Murakami, N., Fukata, J., Usui, T., Naito, Y., Tominaga, T., Nakai, Y., Masui, Y., Nakao, K., Imura, H. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  37. Hindlimb paralytic effects of arginine vasopressin and related peptides following spinal subarachnoid injection in the rat. Long, J.B., Martinez-Arizala, A., Rigamonti, D.D., Holaday, J.W. Peptides (1988) [Pubmed]
  38. Regulation of prolactin secretion in patients with Cushing's disease. A comparative study on the effects of dexamethasone, lysine vasopressin and ACTH on prolactin secretion by the rat pituitary gland in vitro. Lamberts, S.W., de Quijada, M., Visser, T.J. Neuroendocrinology (1981) [Pubmed]
  39. Action of the triglycyl hormonogen of vasopressin (glypressin) in patients with liver cirrhosis and bleeding esophageal varices. Vosmík, J., Jedlicka, K., Mulder, J.L., Cort, J.H. Gastroenterology (1977) [Pubmed]
  40. Mesocaval "H" graft using antogenous vein graft. Nay, H.R., Fitzpatrick, H.F. Ann. Surg. (1976) [Pubmed]
  41. Studies of ACTH secretion control in 116 cases of Cushing's syndrome. Raux, M.C., Binoux, M., Luton, J.P., Gourmelen, M., Girard, F. J. Clin. Endocrinol. Metab. (1975) [Pubmed]
WikiGenes - Universities